sibeprenlimab (VIS649) / Otsuka  >>  Phase 1
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
sibeprenlimab (VIS649) / Otsuka
NCT03719443: First in Human Study to Assess Safety of VIS649 in Healthy Subjects

Completed
1
41
US
VIS649, Placebo
Visterra, Inc.
Immunoglobulin A Nephropathy, IgAN - IgA Nephropathy, IgA Nephropathy
08/19
08/19
ACTRN12620001352998: VIS649-102: A study assessing single doses of VIS649, in healthy adults.

Completed
1
48
 
IQVIA RDS Pty Limited, Visterra, Inc.
Immunoglobulin A Nephropathy
 
 
ChiCTR2200063329: A Randomized, Open-label, Phase 1 Trial to Assess the Pharmacokinetics, Safety and Tolerability, and Pharmacodynamics of Sibeprenlimab Solution Administered Subcutaneously in Chinese Healthy Subjects

Not yet recruiting
1
24
 
200 mg Sibeprenlimab (1 × 1 mL injection) ;400 mg Sibeprenlimab (1 × 2 mL injection) ;600 mg Sibeprenlimab (1 × 1 mL injection and 1 × 2 mL injection)
West China Hospital of Sichuan University; Otsuka Pharmaceutical Development & Commercialization, Inc, Otsuka Pharmaceutical Development & Commercialization, Inc
health Subjects
 
 

Download Options